A Delaware federal judge has barred Amneal Pharmaceuticals from marketing a generic version of Galderma Laboratories’ Oracea acne drug through 2025, finding that the drug infringed under the equitable doctrine of equivalents.

The Aug. 27 opinion from U.S. District Chief Judge Leonard P. Stark of the District of Delaware, made public on Aug. 31, followed a five-day bench trial in February and capped Galderma’s 18-month effort in the U.S. District Court for the District of Delaware to protect Oracea, which generates sales of nearly $300 million per year.